Anavex Life Sciences (AVXL) Net Cash Flow Growth (3y) (2013 - 2025)
Anavex Life Sciences (AVXL) Net Cash Flow Growth (3y) (2013 - 2025) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
NCF Growth (3y) (Qtr) |
| 1 |
Alterity Therapeutics |
814,307.08 Bn |
814,307.05 Bn |
- |
- |
| 2 |
Belite Bio |
55,320.00 Bn |
55,320.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,149.72 Bn |
17,149.72 Bn |
- |
- |
| 4 |
Legend Biotech |
3,590.00 Bn |
3,589.71 Bn |
242.10 Mn |
89.97% |
| 5 |
Akari Therapeutics |
1,650.72 Bn |
1,650.72 Bn |
- |
-13.44% |
| 6 |
Evaxion A |
1,522.09 Bn |
1,522.07 Bn |
- |
- |
| 7 |
Psyence Biomedical |
229.39 Bn |
229.38 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
113.09 Bn |
105.85 Bn |
2.59 Bn |
33.37% |
| 9 |
Abivax |
90.15 Bn |
90.15 Bn |
- |
- |
| 10 |
Anavex Life Sciences |
221.68 Mn |
89.93 Mn |
- |
93.72% |
| Date | Value |
|---|
| Dec 31, 2025 |
93.72% |
| Sep 30, 2025 |
32.94% |
| Jun 30, 2025 |
-367.23% |
| Mar 31, 2025 |
-62.34% |
| Dec 31, 2024 |
-128.12% |
| Sep 30, 2024 |
-6.41% |
| Jun 30, 2024 |
-26.15% |
| Mar 31, 2024 |
-29.14% |
| Dec 31, 2023 |
-33.90% |
| Sep 30, 2023 |
-62.96% |
| Jun 30, 2023 |
8.53% |
| Mar 31, 2023 |
135.11% |
| Dec 31, 2022 |
-45.02% |
| Sep 30, 2022 |
-84.85% |
| Jun 30, 2022 |
-27.65% |
| Mar 31, 2022 |
55.32% |
| Dec 31, 2021 |
24.29% |
| Sep 30, 2021 |
-23.46% |
| Jun 30, 2021 |
681.75% |
| Mar 31, 2021 |
140.53% |
